<DOC>
	<DOCNO>NCT01055704</DOCNO>
	<brief_summary>This single-center , randomize , double blind , placebo-controlled study evaluate effect placebo , codeine , methylnaltrexone codeine methylnaltrexone gastrointestinal motility colonic transit solid healthy human subject . The hypothesis : 1 . Methylnaltrexone administer subcutaneously enhance gastrointestinal motility acceleration overall colonic transit , ascend colon empty solid healthy human . 2 . Methylnaltrexone significantly accelerate colonic transit delay codeine</brief_summary>
	<brief_title>Effect Methylnaltrexone GI Transit Healthy Volunteers</brief_title>
	<detailed_description>Methodology Following initial screen visit ( visit 1 ) , participant randomize study medication , either 0.30mg/kg methylnaltrexone subcutaneously placebo daily 30 mg codeine orally placebo take four time daily total five day . Participants randomly assign study medication allocation conceal . A urine pregnancy test perform female child bear potential within 48 hour prior receipt study medication . Note females status post bilateral tubal ligation , hysterectomy postmenopausal exempt test . Study medication administer study med day 1 , 2 3 ( visit 2 , 3 4 ) Clinical Research Unit ( CRU ) . Participants return scintigraphic assessment gastric , small bowel colonic transit solid study med day 4 5 ( visit 5 6 ) . The transit study undertake 48 hour time period ; study medication give final day transit ( visit 7 ) . Investigational product , dosage , mode administration , duration treatment 0.30 mg/kg methylnaltrexone placebo subcutaneously daily 30 mg codeine placebo orally four time daily five consecutive day . Treatment group 1. placebo + placebo ( 8 participant ) 2. placebo + codeine 120mg ( 8 participant ) 3. methylnaltrexone 0.30 mg/kg + placebo ( 16 participant ) 4. methylnaltrexone 0.30 mg/kg + codeine 120 mg ( 16 participant ) Efficacy assessment 1 . Scintigraphic gastrointestinal colonic transit 2 . Assessment bowel pattern frequency consistency make patient use bowel pattern diary Safety assessments No safety assessment ( routine laboratory analysis , ECG etc ) perform methylnaltrexone codeine FDA approve medication Statistical analysis The overall effect methylnaltrexone treatment primary secondary response measure assess use analysis covariance ( ANCOVA ) suitable transformation skewness distribution measure response necessary ( e.g. , ANCOVA rank arcsine square root transformation proportion marker colon 6 hour ) . The covariates consider inclusion analysis age , gender body mass index . An priori anticipate contrast ( overall drug vs. placebo ) examine ( α = 0.05 ) . The specific comparison methylnaltrexone vs placebo codeine v codeine plus methylnaltrexone significant interest , since relate specific hypothesis , change α 0.05 plan .</detailed_description>
	<mesh_term>Codeine</mesh_term>
	<mesh_term>Methylnaltrexone</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>Inclusion Criteria Males nonpregnant , nonbreastfeeding female 1865 year old No functional GI disorder short Bowel Disease Questionnaire ( BDQ ) A BMI great 22.0 Exclusion criterion Structural metabolic diseases/conditions affect gastrointestinal system functional gastrointestinal disorder . The short version Bowel Disease Questionnaire ( BDQ ) exclude functional GI disorder . More three positive response exclude participation . Unable withdraw follow medication 48 hour prior study entry : Any medication alters GI transit include limited laxative , magnesium aluminumcontaining antacid , prokinetics , erythromycin , narcotic , anticholinergic , tricyclic antidepressant , SSRI new antidepressant ; analgesic drug include opiate , NSAID , COX 2 inhibitor ( note : Tylenol permit ) ; GABAergic agent benzodiazepine . Note : Concomitant medication review case case basis study physician . Subjects consider investigator alcoholic remission know substance abuser . Alcohol must avoid seven day prior begin study medication completion study . Subjects participate another clinical study within past 30 day . Clinical evidence ( include physical exam review medical history ) significant cardiovascular , respiratory , renal , hepatic , pulmonary , gastrointestinal , hematological , neurological , psychiatric , disease interfere objective study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Methylnaltrexone</keyword>
	<keyword>Codeine</keyword>
	<keyword>Gastrointestinal motility</keyword>
	<keyword>Colonic transit</keyword>
</DOC>